Publications by authors named "Eriko Akaza"
Purpose: To evaluate the efficacy of intravitreal ranibizumab (IVR) for subfoveal polypoidal choroidal vasculopathy (PCV) in eyes with a best corrected visual acuity (BCVA) of 0.6 (logMAR 0.22) or better.
View Article and Find Full Text PDFPurpose: To evaluate the visual outcomes and changes in abnormal vascular networks and polypoidal lesions of polypoidal choroidal vasculopathy (PCV) 3 years after photodynamic therapy (PDT).
Methods: We studied 43 eyes of 43 patients with PCV for 3 years. Fundus appearance, fluorescein angiography (FA) and indocyanine green angiography (IA) findings, and visual acuity (VA) before the initial PDT were compared with those 3 months, 1 year, 2 years, and 3 years after treatment.
Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.
Graefes Arch Clin Exp Ophthalmol
September 2010
Background: Polypoidal choroidal vasculopathy (PCV) is considered to be a good indication for photodynamic therapy (PDT). We evaluated pre-PDT factors predicting better visual acuity (VA) 1 year after PDT in patients with PCV.
Methods: We evaluated 181 eyes of 181 patients who underwent PDT and were followed up for 1 year.
Purpose: Vascular endothelial growth factor (VEGF) concentrations in various regions of the vitreous were examined in patients with diabetic macular edema (DME) to explore the possibility of a concentration gradient in the vitreous.
Methods: Vitreous samples were collected during vitrectomy from 71 eyes of 71 patients with DME and without posterior vitreous detachment who had not undergone panretinal photocoagulation. Vitreous samples were collected from the premacular vitreous and mid-vitreous (group A, 35 eyes), and from the premacular vitreous and peripheral cortical vitreous (group B, 36 eyes).
Purpose: This study evaluated the results of photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) 24 months or more after treatment.
Methods: The study involved 47 eyes of 47 patients with PCV followed for 24 months or more after the first PDT. Fundus appearance, indocyanine green angiographic findings, and visual acuity (VA) were compared before PDT, and then at 3 months, 12 months, and the final visit after the first PDT.
[An adult case of ophthalmoplegic migraine with the pseudo-Graefe sign].
Nippon Ganka Gakkai Zasshi
August 2007
Purpose: An adult case of ophthalmoplegic migraine is reported.
Case: A 35-year-old man presented at our hospital with a 2-day history of double vision. He had a history of double vision following migraine which completely resolved within a week, occurring every few years since the age of 13.
Purpose: To determine the efficacy of photodynamic therapy (PDT) with verteporfin for polypoidal choroidal vasculopathy (PCV).
Methods: PDT was performed in 35 patients (35 eyes) with PCV. We evaluated the number of treatments and compared visual acuity (VA), ophthalmological findings, and changes in polypoidal lesions and branching vascular networks by measuring lesion diameters using Heidelberg retina angiography before PDT, and then every 3 months for 1 year after PDT.
Purpose: To study sighting dominance by comparing macular disease patients undergoing surgical treatment with controls.
Methods: We studied visual acuity and sighting dominance in 92 macular disease patients, 27 of whom were assessed for both outcomes. We also studied visual acuity and sighting dominance in 412 controls.
Purpose: To evaluate the relationship between pulsation and the fundus lesion in polypoidal choroidal vasculopathy (PCV).
Objective And Methods: We studied 26 eyes with PCV by indocyanine green angiography (IA) with a heidelberg retina angiograph(HRA). The 26 eyes were classified into two groups; pulsatile PCV and non-pulsatile PCV.